| 4WV1: reference: Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity., Yin Y, Djakovic S, Marsters S, Tien J, Peng J, Tremayne J, Lee G, Neve RM, Wu Y, Merchant M, Ashkenazi A, Carter PJ, Mol Cancer Ther. 2015 Aug 12. PMID: 26269606 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).